CGEM Cullinan Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CGEM matters now
Cullinan Therapeutics, Inc. (CGEM) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.13 with -1.36% on the session and $1.11B in market capitalization; recent performance reads 1-month +5.99% and YTD +45.22%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-49.7M, and EPS of $-0.84. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.3%.
The latest indexable market news headline is "Cullinan Therapeutics: Heading Toward Paydirt" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Doyle Mittie filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.43
P/S
0.00
EV/EBITDA
-3.86
DCF Value
$1.44
FCF Yield
-19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.5%
ROA
-54.9%
ROIC
-65.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-49.7M | $-0.84 |
| Q4 2025 | $0.00 | $-50.7M | $-0.86 |
| FY 2025 | $0.00 | $-219.9M | $-3.72 |
| Q3 2025 | $0.00 | $-50.6M | $-0.86 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.00
Target (Median)
$30.00
Target Range
$28.00 - $37.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Exchange
—
Beta
0.01
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.